Incysus Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference
04 sept. 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Strengthens Board of Directors With Appointment of Pharmaceutical Veteran Peter C. Brandt
06 août 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Appoints Rozanna Yaing As Senior Vice President, Quality And Regulatory Affairs
02 juil. 2019 08h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Announces Publication of U.S. Patent for Drug Resistant Immunotherapy (DRI) Technology
19 juin 2019 08h00 HE
|
Incysus Therapeutics, Inc.
US Patent and Trademark Office Issues U.S. Patent Covering Drug Resistant Immunotherapy (DRI) TechnologyClaims Provide Initial Protection for Incysus’ Novel DRI PlatformIncysus Controls Exclusive...
Incysus Therapeutics to Present at Jefferies 2019 Global Healthcare Conference
22 mai 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Lawrence Lamb, Ph.D., Incysus Therapeutics Scientific Co-Founder to Present at Allogenic Cell Therapies Summit 2019 (ACTS)
02 mai 2019 08h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Announces FDA Approval of IND Application for a Novel Gamma-Delta (γδ) T Cell Therapy for Treatment of Patients With Newly-Diagnosed Glioblastoma
01 avr. 2019 08h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Present New Data at the American Association for Cancer Research (AACR) Annual Meeting 2019
19 mars 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, March 19, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Gamma-Delta T Cell Immunotherapy Pioneer, Lawrence Lamb, PhD, to Join Incysus Therapeutics as Chief Scientific Officer
03 janv. 2019 14h30 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Completes Series A Financing and Announces the Appointment of Travis Whitfill, MPH to Its Board of Directors
03 janv. 2019 14h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...